Archives of Virology

, Volume 156, Issue 2, pp 183–202

Adjuvants and delivery systems in veterinary vaccinology: current state and future developments

Authors

    • Department of Veterinary Diagnostics and Research, National Veterinary InstituteTechnical University of Denmark
  • Laurence Dedieu
    • CIRAD, UMR CMAEE Contrôle des Maladies Animales
  • Nicholas Johnson
    • Veterinary Laboratories Agency, New Haw
  • Marie-Frédérique Le Potier
    • Anses Laboratoire de PloufraganUnité virologie et immunologie porcines
  • Michael Mockey
    • CIRAD, UMR CMAEE Contrôle des Maladies Animales
  • Franco Mutinelli
    • Histopathology DepartmentIstituto Zooprofilattico Sperimentale delle Venezie
  • Thomas Vahlenkamp
    • Friedrich-Loeffler-Institute, Federal Research Institute for Animal Health
  • Marta Vascellari
    • Histopathology DepartmentIstituto Zooprofilattico Sperimentale delle Venezie
  • Nanna Skall Sørensen
    • Department of Veterinary Diagnostics and Research, National Veterinary InstituteTechnical University of Denmark
Brief Review

DOI: 10.1007/s00705-010-0863-1

Cite this article as:
Heegaard, P.M.H., Dedieu, L., Johnson, N. et al. Arch Virol (2011) 156: 183. doi:10.1007/s00705-010-0863-1

Abstract

Modern adjuvants should induce strong and balanced immune responses, and it is often desirable to induce specific types of immunity. As an example, efficient Th1-immunity-inducing adjuvants are highly in demand. Such adjuvants promote good cell-mediated immunity against subunit vaccines that have low immunogenicity themselves. The development of such adjuvants may take advantage of the increased knowledge of the molecular mechanisms and factors controlling these responses. However, knowledge of such molecular details of immune mechanisms is relatively scarce for species other than humans and laboratory rodents, and in addition, there are special considerations pertaining to the use of adjuvants in veterinary animals, such as production and companion animals. With a focus on veterinary animals, this review highlights a number of approaches being pursued, including cytokines, CpG oligonucleotides, microparticles and liposomes.

Supplementary material

705_2010_863_MOESM1_ESM.pdf (822 kb)
Supplementary material (PDF 821 kb)

Copyright information

© Springer-Verlag 2010